Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.

Long-term inhaled corticosteroid therapy for COPD may have serious adverse effects

06 Dec 2019

Exposure to inhaled corticosteroid (ICS) therapy for chronic obstructive pulmonary disease (COPD) in the long term may be detrimental to patients, being associated with elevated risks of diabetes, its progression and osteoporosis, as shown in a study.

The study used data from two large UK databases of patients (age ≥40 years) initiating ICS or long-acting bronchodilator (LABD) for COPD. Treatment was assessed in relation to the risk of diabetes onset (n=17,970), diabetes progression (n=804) or osteoporosis incidence (n=19,898).

All patients had available ≥1-year baseline and ≥2-year outcome data, with a median follow-up of 3.7–5.6 years per treatment group.

Conditional proportional hazards regression revealed that compared with LABD, ICS was associated with an increased risk of diabetes onset (adjusted hazard ratio [HR], 1.27, 95 percent confidence interval [CI], 1.07-1.50). There was no overall risk increase observed for diabetes progression (adjusted HR, 1.04, 95 percent CI, 0.87–1.25) and incident osteoporosis (adjusted HR, 1.13, 95 percent CI, 0.93–1.39).

However, a dose-response relationship for all three outcomes became apparent at mean ICS exposures of 500 µg/day (vs <250 µg/day, fluticasone propionate-equivalent). This pattern of association was not evident for cumulative ICS exposures.

The present data raise uncertainty with regard to the risk-benefit ratio for ICS in COPD. Hence, researchers stressed that careful selection of COPD therapies be practiced and that clinicians prescribe ICS only when indicated (within current GOLD strategy recommendations) and at the lowest possible doses.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 2 days ago
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.
01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
01 Aug 2020
Ensituximab, a chimeric monoclonal antibody targeting a variant of MUC5AC, shows modest clinical activity with good safety profile in patients with refractory colorectal cancer, according to data from a phase II study.
Roshini Claire Anthony, 30 Jul 2020

Frailty may indicate an increased risk of death from COVID-19, results of the COPE* study showed.